Efficacy Analysis of Unrelated Cord Blood Transplantation in the Treatment of Juvenile Myelomonocytic Leukemia.
10.19746/j.cnki.issn.1009-2137.2020.04.007
- Author:
Si-Qi CHENG
1
;
Xiao-Yu ZHU
2
;
Bao-Lin TANG
2
;
Hui-Lan LIU
2
;
Wen YAO
2
;
Guang-Yu SUN
2
;
Zi-Min SUN
3
,
4
Author Information
1. Department of Hematology, The Provincial Hospital Affiliated to Anhui Medical University，Hefei 230001, Anhui Province, China.
2. Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230001, Anhui Province, China.
3. Department of Hematology, The Provincial Hospital Affiliated to Anhui Medical University，Hefei 230001, Anhui Province, China,Department of Hematology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230001, Anhui Province, China,E-mail: zmsun_vip@
4. com.
- Publication Type:Journal Article
- MeSH:
Child;
Child, Preschool;
Cord Blood Stem Cell Transplantation;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Infant;
Leukemia, Myelomonocytic, Juvenile;
Male;
Retrospective Studies;
Transplantation Conditioning
- From:
Journal of Experimental Hematology
2020;28(4):1123-1126
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) in the treatment of Juvenile myelomonocytic leukemia (JMML).
METHODS:The clinical data of 5 children with JMML who were treated with unrelated UCBT from October 2011 to July 2019 were retrospectively analyzed. The age of onset for the five children (male) ranged from 0.4 to 5.0 years old, with a median age of 1.5 years old. All the patients received myeloablative conditioning regimen without ATG to whom cyclosporine A (CsA) with short-term mycophenolate mofetil (MMF) was given for GVHD prophylaxis.
RESULTS:Four children acquired engraftment. One patient received secondary haploidentical hematopoietic stem cell transplantation because of the failure in the first unrelated UCBT. Grade Ⅲ to Ⅳ aGVHD occurred in 2 cases and was controlled, and none of the patients developed cGVHD. Three cases achieved long-time disease free survival，and no patient relapsed.
CONCLUSION:UCBT is an effective treatment for children with JMML.
